>
Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Allopurinol (Zyloprim®) is a xanthine oxidase inhibitor used in veterinary medicine primarily in dogs and cats to reduce uric acid production. It is most commonly utilized in the management and prevention of urate urolithiasis in dogs and as a long-term adjunctive therapy for leishmaniasis in both dogs and cats.
Allopurinol does not provide analgesic, anti-inflammatory, or antimicrobial effects. Instead, its clinical benefit is derived from altering purine metabolism, making it a disease-modifying agent rather than a symptomatic treatment. For this reason, it is often used for extended periods and requires dietary and laboratory monitoring.
Mechanism of Action (MOA): Allopurinol and its active metabolite, oxypurinol, inhibit the enzyme xanthine oxidase, which is responsible for converting hypoxanthine and xanthine into uric acid. By reducing uric acid formation, urinary urate concentrations decrease, lowering the risk of urate stone formation. In leishmaniasis, allopurinol interferes with parasite purine metabolism, leading to incorporation of toxic purine analogs into protozoal RNA and inhibition of parasite replication.
Indications
Allopurinol is used in dogs and cats for conditions associated with abnormal purine metabolism or diseases in which inhibition of xanthine oxidase provides therapeutic benefit. Its use is typically long-term and often requires dietary modification and regular monitoring.
- Urate urolithiasis in dogs: Used for the prevention and, in some cases, dissolution of ammonium urate uroliths by reducing uric acid production. It is especially indicated in breeds predisposed to hyperuricosuria, such as Dalmatians, and should always be combined with a low-purine, urine-alkalinizing diet.
- Prevention of recurrent urate stones (dogs): Long-term, low-dose therapy may be used to reduce recurrence in dogs with a history of urate urolithiasis, provided adequate hydration and dietary management are maintained.
- Adjunctive treatment of leishmaniasis (dogs and cats): Used as a long-term antiparasitic agent to suppress Leishmania replication. Allopurinol improves clinical signs and reduces parasite load but does not achieve complete parasitological cure; relapse is common if therapy is discontinued.
- Maintenance therapy in leishmaniasis (dogs): Often continued for months to years following combination therapy with antimonial drugs or miltefosine to maintain clinical remission.
Dosage (Reference)
Dog
In dogs, allopurinol dosing varies according to the clinical indication. Careful dose selection and dietary management are essential, especially during long-term therapy, to avoid xanthine crystal or stone formation.
| Indication | Route | Dose | Clinical notes |
|---|---|---|---|
| Dissolution of urate uroliths | PO | 15 mg/kg every 12 hours |
Short-term protocol (up to 4 weeks). Must be combined with a low-purine, alkalinizing, diuretic diet to be effective. |
| Prevention of urate urolith recurrence | PO | 5–7 mg/kg every 12–24 hours |
Preferred for long-term use. Lower doses reduce the risk of xanthine urolith formation. |
| Leishmaniasis (adjunctive therapy) | PO | 10–15 mg/kg every 12 hours |
Typically administered for 6–12 months in combination with antimonial drugs or miltefosine. |
| Leishmaniasis (monotherapy) | PO | 5–20 mg/kg every 12 hours |
Does not result in complete cure. Relapse is common if treatment is discontinued. |
• Initiate therapy at 5 mg/kg PO every 12 hours in dogs with renal dysfunction.
• Prolonged doses >30 mg/kg/day increase the risk of xanthine urolithiasis.
• Always combine chronic therapy with a low-purine diet and increased water intake.
• Periodic urinalysis (pH ≥7) and imaging are recommended during long-term use.
Cat
In cats, allopurinol is used primarily as an extra-label treatment
for leishmaniasis. Clinical experience is limited compared to dogs,
so cautious dosing and close monitoring are recommended.
| Indication | Route | Dose | Clinical notes |
|---|---|---|---|
| Leishmaniasis (extra-label) | PO | 10–20 mg/kg every 12 or 24 hours |
Long-term therapy; dosing interval may be adjusted based on tolerance and clinical response. |
• Use the lowest effective dose, especially during prolonged therapy.
• Monitor for gastrointestinal signs and changes in renal or hepatic parameters.
• Ensure adequate hydration throughout treatment.
Warnings & Precautions
Allopurinol should be used with caution in dogs and cats due to its effects on purine metabolism and the potential for renal and hepatic complications, particularly during long-term therapy.
- Renal dysfunction: Allopurinol should be used cautiously in dogs and cats with renal disease, as reduced clearance may increase the risk of adverse effects. Lower starting doses and closer monitoring are recommended in these patients.
- Hepatic dysfunction: Use cautiously in patients with hepatic impairment. Dosage adjustments and periodic monitoring of liver enzymes are advised due to hepatic involvement in drug metabolism.
- Xanthine urolith formation: Prolonged or high-dose therapy may result in xanthinuria and formation of xanthine uroliths, especially when dietary purine intake is not adequately restricted.
- Dietary management: A low-purine diet is strongly recommended during chronic administration to minimize the risk of urinary crystal formation and urolithiasis.
- Urate uroliths with portovascular anomalies: Allopurinol does not appear to be effective in dissolving urate uroliths in dogs with portosystemic shunts and should not be relied upon as sole therapy in these cases.
- Hypersensitivity reactions: Treatment should be discontinued immediately if signs such as rash, lethargy, fever, or other unexplained systemic reactions are observed.
- Long-term therapy: Chronic administration requires periodic monitoring, including CBC, serum biochemistry, and urinalysis, to detect early renal, hepatic, or hematologic abnormalities.
- Hydration status: Adequate access to fresh water must be ensured at all times to reduce the risk of crystalluria and renal complications.
- Pregnancy and lactation: Safety has not been established in pregnant or lactating dogs and cats; use only when the potential maternal benefits outweigh the potential risks to offspring.
Drug Interactions
Allopurinol has multiple potential drug interactions in dogs and cats that may increase the risk of adverse effects or alter the therapeutic response. When used concurrently with other medications, careful dose adjustment and close clinical monitoring are recommended.
- Azathioprine and mercaptopurine: Allopurinol inhibits the metabolism of mercaptopurine (the active metabolite of azathioprine), leading to increased serum concentrations and a high risk of bone marrow suppression. Concurrent use should be avoided when possible; if unavoidable, substantial dose reduction of the immunosuppressive agent and close monitoring are required.
- Angiotensin-converting enzyme (ACE) inhibitors: Concurrent use has been associated in humans with an increased risk of hypersensitivity reactions to allopurinol. The veterinary significance is unclear, but caution and monitoring are advised in dogs and cats.
- Aminopenicillins (e.g., amoxicillin, ampicillin): Increased risk of hypersensitivity reactions has been reported in humans receiving this combination. Although veterinary data are limited, patients should be monitored for signs of adverse reactions.
- Diuretics (e.g., furosemide, hydrochlorothiazide): Concurrent use may increase serum concentrations of allopurinol and its active metabolite, potentially increasing the risk of adverse effects.
- Cyclosporine: Allopurinol may increase cyclosporine concentrations, which can enhance the risk of cyclosporine-related toxicity. Monitoring of clinical response and adverse effects is recommended.
- Cyclophosphamide: Concurrent use may increase the risk of bone marrow suppression, and hematologic monitoring is recommended when these drugs are used together.
- Theophylline and aminophylline: Allopurinol may decrease the metabolism of methylxanthines, resulting in increased serum concentrations and a higher risk of toxicity.
- Uricosuric agents (e.g., probenecid): These agents may increase the renal excretion of oxypurinol and reduce xanthine oxidase inhibition. While this may decrease allopurinol effectiveness, additive uric acid–lowering effects may occur.
- Urinary acidifiers: Acidification of urine may reduce uric acid solubility and increase the risk of urolith formation, particularly during long-term allopurinol therapy.
- Aluminum hydroxide: Concurrent administration may reduce gastrointestinal absorption of allopurinol. Separate administration times may help minimize this interaction.
Side Effects & Overdose
Side Effects
Adverse effects associated with allopurinol in dogs and cats are generally uncommon when appropriate doses are used and a low-purine diet is maintained. Most reported adverse effects are dose-related or associated with long-term therapy.
- Gastrointestinal effects: The most commonly reported adverse effects include nausea, vomiting, anorexia, and diarrhea. These effects are usually mild and may be reduced by administering the drug with food.
- Xanthinuria and urolithiasis (dogs): Prolonged administration, especially at doses exceeding 30 mg/kg/day, may lead to increased urinary xanthine concentrations, resulting in xanthine crystalluria, renal mineralization, or xanthine urolith formation.
- Renal effects: Renal mineralization and urolithiasis have been reported in a small percentage of dogs receiving long-term therapy, particularly when dietary purine intake is not adequately restricted.
- Hepatic effects: Increases in liver enzyme activity have been reported infrequently and warrant dose adjustment or discontinuation if clinically significant.
- Hypersensitivity reactions: Although rare, hypersensitivity reactions may occur and can include dermatologic signs or systemic illness. Discontinue therapy if suspected.
Overdose
Information regarding acute allopurinol toxicity in dogs and cats is limited. Overdose effects are primarily gastrointestinal and neurologic in nature and are generally dose-dependent.
- Clinical signs: Vomiting has been observed in dogs at doses exceeding 44 mg/kg. Tremors and generalized discomfort may also occur with excessive dosing.
- Renal risk: High or prolonged supratherapeutic doses may increase the risk of xanthine accumulation and subsequent renal complications.
- Antidote: There is no specific antidote for allopurinol overdose.
- Management: Treatment is supportive and may include gastrointestinal decontamination when appropriate, maintenance of hydration, and monitoring of renal and hepatic function.
- Dialysis: Allopurinol is dialyzable and dialysis may be considered in severe cases.
Key Notes
Practical clinical considerations that support safe and effective long-term use of allopurinol in dogs and cats, particularly when used for urolith prevention or leishmaniasis management:
- Dietary management is essential: Long-term therapy should always be combined with a low-purine diet to reduce the risk of xanthine accumulation and urinary complications.
- Delayed clinical benefit: Therapeutic effects, especially in leishmaniasis, may take weeks to become evident; lack of rapid improvement does not necessarily indicate treatment failure.
- Long-term therapy considerations: Treatment courses often extend for months, and in some cases years, requiring ongoing monitoring and client compliance.
- Hydration support: Adequate water intake should be encouraged to reduce urinary concentration of metabolites and support renal clearance.
- Dose individualization: Initiate therapy at the lowest effective dose, particularly in animals with renal compromise, and adjust based on response and tolerability.
- Not curative for leishmaniasis: Allopurinol suppresses clinical disease and parasite replication but does not eliminate infection when used alone.
- Monitoring improves safety: Periodic assessment of renal function, liver enzymes, and urinalysis improves early detection of adverse effects during chronic use.
